TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03938701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab-800CW
Description: Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab-800CW
Description: Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy.
Study: NCT05838352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
Study: NCT06043102

Intervention type: DEVICE
Group type: OTHER
Intervention: TheraClearX
Description: TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
Study: NCT04958733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone grafting
Description: Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
Study: NCT05619809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thermogenic dietary supplement
Description: Daily ingestion of OxyShred thermogenic dietary supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein supplement
Description: Daily ingestion of protein supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: Daily ingestion of protein supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Daily ingestion of a placebo dietary supplement.
Study: NCT05790200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
Study: NCT05837130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection and an optional cerebrospinal fluid (CSF) collection
Description: No study drug will be administered to study participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: No study drug will be administered to study participants.
Study: NCT05193435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Description: Pelvic floor exercises for types I and II muscle fibers will be performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization exercises
Description: Lumbar spinal stabilization exercises will be performed
Study: NCT05601193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma
Description: autologous PRP preparation was done by segregation of PRP following the centrifugation
Study: NCT05370352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation treatment
Description: Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation treatment
Description: Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation
Study: NCT06379139

Intervention type: OTHER
Intervention: •Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube
Description: Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
Study: NCT05919069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Study: NCT06247579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary polystyrene microplastics from disposable plastic tableware
Description: Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
Study: NCT06318975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention
Description: All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Alcohol Intervention
Description: All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated and Targeted Text Messages
Description: All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
Study: NCT06298487

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file
Study: NCT06184659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
Study: NCT06436469

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-Based Stress Reduction (MBSR) Program
Description: The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
Study: NCT05784363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Study: NCT06568770

Intervention type: DRUG
Group type: OTHER
Intervention: USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK
Description: With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected

Intervention type: DRUG
Group type: OTHER
Intervention: PERICAPSULAR NERVE BLOCK
Description: an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected.
Study: NCT05682352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 158968
Description: IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 158968
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection
Study: NCT04965896

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control meal
Description: Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nut meal
Description: Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
Study: NCT06396091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered intravenously on day 1 then every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.
Study: NCT04532489

Intervention type: DRUG
Group type: OTHER
Intervention: FNP-59
Description: FNP-59, a radiotracer, is administered for PET/CT scans.
Study: NCT05324254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
Study: NCT04992897

Intervention type: DEVICE
Intervention: Remote Electrical Neuromodulation (REN)
Description: Acute migraine treament

Intervention type: DEVICE
Intervention: Remote Electrical Neuromodulation (REN)
Description: Acute migraine treament

Intervention type: DEVICE
Intervention: Remote Electrical Neuromodulation (REN)
Description: Acute migraine treament

Intervention type: DEVICE
Intervention: Remote Electrical Neuromodulation (REN)
Description: Acute migraine treament
Study: NCT05409664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity adoption
Description: webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring
Description: Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
Study: NCT04751786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRECIOUS-01
Description: Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
Study: NCT06543095

Intervention type: OTHER
Intervention: Pain level
Description: Post-operative pain levels of the patients with detected using VAS score.

Intervention type: OTHER
Intervention: Pain level
Description: Post-operative pain levels of the patients with detected using VAS score.
Study: NCT04930536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib capsule
Description: The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
Study: NCT05620706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC3 CAR-T cells
Description: patients treated with GPC3 CAR-T cells
Study: NCT04958733

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Absence of autologous bone grafting
Description: Donor sites will be left unfilled
Study: NCT05784428

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single fraction SABR
Description: Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Multiple fraction SABR
Description: Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QoL reporting alone
Description: Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QoL reporting, symptom screen and healthcare provider intervention
Description: Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
Study: NCT06128525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo planning mpMRI of prostate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo RP
Study: NCT05762666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nociception level index monitor
Description: The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
Study: NCT06368492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis script
Description: All participants will receive a brief hypnotic induction aimed at producing analgesia before the second administration of CPT
Study: NCT05602220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain training
Description: Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain training
Description: Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced breathing
Description: After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced breathing
Description: After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
Study: NCT05589246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: regional analgesia with cryolesia
Description: The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves